VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment for Cystic Fibrosis in Children

01/11/2022 | 03:50am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
VERTEX PHARMACEUTICALS 0.60% 270.28 Delayed Quote.22.26%
VERTEX, INC. 5.34% 11.2395 Delayed Quote.-32.77%
All news about VERTEX PHARMACEUTICALS
05/23Top Midday Gainers
MT
05/23Catalyst Biosciences Stock Surges After Vertex Pharmaceuticals Buys Catalyst's Compleme..
MT
05/23Catalyst Biosciences Shares Soar After Complement Portfolio Sale
DJ
05/23VERTEX PHARMACEUTICALS INC / MA : Other Events (form 8-K)
AQ
05/23Catalyst Biosciences Sells Complement Portfolio for $60 Million
AQ
05/23SVB Securities Initiates Vertex Pharmaceuticals at Market Perform With $265 Price Targe..
MT
05/23VERTEX PHARMACEUTICALS INCORPORATED : VRTX) acquired Complement Portfolio of Catalyst Bio..
CI
05/19Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
05/18VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (for..
AQ
05/18Suketu Upadhyay Elected to Vertex Board of Directors
BU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2022 8 599 M - -
Net income 2022 3 253 M - -
Net cash 2022 10 823 M - -
P/E ratio 2022 21,2x
Yield 2022 -
Capitalization 68 665 M 68 665 M -
EV / Sales 2022 6,73x
EV / Sales 2023 5,83x
Nbr of Employees 3 900
Free-Float 99,6%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 268,48 $
Average target price 292,59 $
Spread / Average Target 8,98%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS22.26%68 665
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546
GENMAB A/S-19.24%20 071